Results 201 to 210 of about 280,132 (264)

Primary central nervous system lymphoma and tumefactive demyelinating lesions in multiple sclerosis: a retrospective observational cohort study. [PDF]

Front Oncol
Chen Y, Shen L, Chen S, Zheng S, Xie J, Zheng S.   +5 more
europepmc   +1 more source

Targeting a Myeloid–Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections

Advanced Science, EarlyView.
Periprosthetic joint infection establishes a sophisticated immunosuppressive network between CXCR4+ PMN‐MDSCs and Bregs, inducing profound CD8+ T cell paralysis. Alendronate effectively disrupts this CXCR4+ PMN‐MDSC–Breg axis by targeting STAT3, thereby restoring local immune surveillance.
Jintao Wu, Shutao Zhang, Yumin Lin, Juyang Jiao, Zhiwei Fu, Qimin Hong, Ziyi Zhao, Xinhua Qu, Fei Su, Bing Yue   +9 more
wiley   +1 more source

Influencing factors for pcr-fluorescent probe detection results in patients with lymph node tuberculosis: A retrospective observational study. [PDF]

Medicine (Baltimore)
Li Q, Luo P, Sun D, Ding C, Ren L.
europepmc   +1 more source

Engineered Au@CeO2 Hybrid Nanoparticles With Microenvironment Dependent Self‐Adjustability for Integration of Tumor‐Specific Photothermal‐Chemodynamic Therapy and Inflammation Prevention

Advanced Science, EarlyView.
An intelligent Au@CeO2 Hybrid Nanoparticles (ACEF) with microenvironment‐dependent self‐adjustability was engineered to not only perform efficient and tumor‐specific photothermal‐chemodynamic therapy for precise tumor elimination, but also serve as a ROS scavenger in healthy tissues around the tumor to avoid the unexpected oxidative damage and ...
Wenyun Mu, Wenjuan Tang, Handan Zhang, Jie Liu, Jiaqi Zhang, Yu Yao, Xiao Fu, Xin Chen, Yanmin Zhang   +8 more
wiley   +1 more source

Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors. [PDF]

Cytotherapy
Murphy D, Bi Y, Patel A, Li Y, Zheng Y, Poston L, Akel S, Kilpatrick C, Lockey T, Zhou S, Bertrand KC, DeRenzo C, Naik S, Sharma A, Talleur AC, Velasquez MP, Triplett BM, Gottschalk S, Selukar S, Epperly R.   +19 more
europepmc   +1 more source

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, EarlyView.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source

Integrating CD45 + CD3+ and CD3 + CD8+ T-cell markers into nomograms for predicting survival in gastroesophageal junction carcinoma. [PDF]

Sci Rep
Song Y, Wang Z, Ma J, Li Y, Su R.
europepmc   +1 more source

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription

Advanced Science, EarlyView.
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue, Xiaohua Jie, Zhiwei Liu, Ruoxin Fang, Shuo Wu, Xiaorong Dong, Shuangbing Xu   +6 more
wiley   +1 more source

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. [PDF]

MAbs
Danquah W, Pichery M, Eden T, Boyance A, Pasquet L, Roure V, Mars M, Marchand A, Gumz E, Gador M, Valente L, Contini M, Czernecki L, Shanmuganathan S, Barron P, Chabot S, Dangl M, Niederfellner G.   +17 more
europepmc   +1 more source

Targeting WDR12 Unleashes T‐Cell‐Mediated Antitumor Activity in Melanoma by Destabilizing CD276

Advanced Science, EarlyView.
WDR12 cooperates with the chaperonin subunit CCT7 to maintain CD276 stability on tumor cells, suppressing T‐cell activity and promoting immune escape. SU14813, a small‐molecule WDR12 inhibitor, reduces CD276 stability and relieves CD276‐mediated T‐cell suppression.
Jie Pan, Ruimin Chang, Meng Zhang, Qian Dong, Guanxiong Zhang, Xiang Chen, Mingliang Chen, Lixia Lu, Xiaowei Liang, Yeye Guo, Juan Su   +10 more
wiley   +1 more source